Sharon J Sha, MD
Neuropsychiatry · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Community Hospital of the Monterey Peninsula · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Sha’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A104145 · Current
Licensed to practise in California · since 2008 · expires 2028-03-31 · Georgetown University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Community Hospital of the Monterey PeninsulaMonterey, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Montage HealthPatients rate it 4 of 5 · 84% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 1.48 (1.22 to 1.74), Jul 2022 – Jun 2024Worse than the national rate — Postoperative acute kidney injury requiring dialysis rate: 3.12 (1.69 to 4.56) · 1,095 cases, Jul 2022 – Jun 2024Worse than the national rate — Postoperative respiratory failure rate: 19.24 (14.17 to 24.3) · 1,118 cases, Jul 2022 – Jun 2024Worse than the national rate — Postoperative sepsis rate: 9.62 (6.42 to 12.82) · 1,086 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.39, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Community Hospital of the Monterey Peninsula
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 1 better, 5 the same, 1 worse of 7 measures. Readmissions: 0 better, 11 the same, 0 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.48 (1.22 to 1.74) | Worse | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 3.12 (1.69 to 4.56) · 1,095 cases | Worse | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 19.24 (14.17 to 24.3) · 1,118 cases | Worse | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 9.62 (6.42 to 12.82) · 1,086 cases | Worse | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.39 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.27 (0.39 to 2.16) · 1,873 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 158.2 (110.65 to 205.75) · 140 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.3 · 74 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 135 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 184 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.7 · 686 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.4 · 1,072 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8 · 328 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.8 · 3,300 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.29 (0.11 to 0.48) · 10,234 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.1 to 0.46) · 10,572 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.25 (1.47 to 5.04) · 2,617 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.37 (1.04 to 3.7) · 2,519 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.21 (0.75 to 3.66) · 744 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.61 (0.06 to 1.17) · 8,715 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.2 · 156 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.28 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.799 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.732 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.7 · 152 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.6 · 625 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 6.3 · 193 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -3.2 · 749 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7 · 1,074 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.5 · 850 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4 (2.7 to 5.8) · 224 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.5 (10.4 to 17.4) · 224 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 153 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.5 · 49 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.2 (10.9 to 18.6) · 711 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (1 to 1.5) · 746 cases | No different | Jan 2024 – Dec 2024 |
What patients said (520 patients answered, 28% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 5 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 75% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 89% |
| Patients who gave a rating of "9" or "10" (high) | 82% |
| Staff "always" explained new medications | 79% |
| Nurses "always" explained things so they could understand | 79% |
| Nurses "always" listened carefully | 77% |
| Nurses "always" treated them with courtesy and respect | 89% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 84% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$27,923
Medicare paid this office $27,923 for 182 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 130 | $16,836 | $115 |
| Long return visit (40+ min) | 32 | $5,416 | $155 |
| New patient visit (60+ min) | 33 | $4,825 | $146 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 11 | $282 | $24 |
Who their Medicare patients are
182 Original Medicare patients in 2024. Average age 78 · Women 52% · Also on Medicaid 15% · Health risk score 1.36. At or below the middle of the specialty; the typical neuropsychiatry clinician is at 1.55.
Conditions among them: Dementia 65% · High blood pressure 62% · Depression 35% · Coronary heart disease 28% · Diabetes 22% · Chronic kidney disease 18% · Cancer 16% · Atrial fibrillation 15% · Stroke 15% · Heart failure 13% · COPD 10%.
The office billed $76,231, Medicare allowed $39,565 and paid $27,923; for 235 services of 6 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 182 | 235 | 78 | 1.36 | $76,231 | $27,923 |
| 2023 | 182 | 217 | 78 | 1.29 | $86,528 | $24,756 |
| 2022 | 229 | 330 | 78 | 1.35 | $165,946 | $38,519 |
| 2021 | 224 | 286 | 79 | 1.39 | $179,970 | $33,650 |
| 2020 | 241 | 343 | 78 | 1.27 | $194,759 | $32,493 |
| 2019 | 234 | 329 | 78 | 1.14 | $53,501 | $32,759 |
| 2018 | 248 | 344 | 78 | 1.14 | $55,584 | $34,363 |
| 2017 | 264 | 363 | 77 | 1.27 | $99,209 | $35,708 |
| 2016 | 332 | 489 | 76 | 1.27 | $161,467 | $47,157 |
| 2015 | 372 | 634 | 76 | 1.19 | $199,634 | $61,431 |
| 2014 | 225 | 495 | 75 | 1.17 | $148,428 | $47,152 |
| 2013 | 114 | 192 | 74 | 1.05 | $71,461 | $20,207 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| Long return visit (40+ min) | 154 | $19,868 | $112 |
| New patient visit (60+ min) | 34 | $4,739 | $139 |
2022: 3 services
| Long return visit (40+ min) | 178 | $26,200 | $111 |
| New patient visit (60+ min) | 77 | $11,435 | $149 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 11 | $354 | $25 |
2021: 3 services
| Long return visit (40+ min) | 171 | $23,902 | $117 |
| New patient visit (60+ min) | 55 | $8,491 | $154 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 13 | $599 | $30 |
2020: 6 services
| Long return visit (40+ min) | 161 | $17,993 | $94 |
| New patient visit (60+ min) | 54 | $7,130 | $132 |
| Long return visit (40+ min) | 26 | $2,635 | $98 |
| Telephone medical discussion with physician, 21-30 minutes | 17 | $1,250 | $74 |
| Return visit (30+ min) | 20 | $810 | $40 |
| Telehealth originating site facility fee | 11 | $217 | $20 |
2019: 3 services
| Long return visit (40+ min) | 178 | $20,442 | $90 |
| New patient visit (60+ min) | 74 | $9,669 | $131 |
| Extended office or other outpatient service, first hour | 17 | $1,887 | $111 |
2018: 4 services
| Long return visit (40+ min) | 148 | $14,518 | $83 |
| New patient visit (60+ min) | 68 | $8,849 | $130 |
| Long return visit (40+ min) | 60 | $6,085 | $100 |
| New patient visit (60+ min) | 21 | $3,161 | $151 |
2017: 3 services
| Long return visit (40+ min) | 189 | $20,583 | $86 |
| New patient visit (60+ min) | 87 | $12,043 | $138 |
| Extended office or other outpatient service, first hour | 17 | $2,146 | $107 |
2016: 6 services
| Long return visit (40+ min) | 198 | $22,057 | $89 |
| New patient visit (60+ min) | 109 | $14,654 | $134 |
| Extended office or other outpatient service, first hour | 28 | $2,603 | $81 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,458 | $121 |
| Return visit (30+ min) | 21 | $1,219 | $53 |
| Removal of cerebrospinal fluid with lower back spinal tap for diagnostic test | 15 | $1,052 | $70 |
2015: 5 services
| Long return visit (40+ min) | 242 | $27,474 | $86 |
| New patient visit (60+ min) | 168 | $22,930 | $136 |
| Extended office or other outpatient service, first hour | 78 | $6,450 | $81 |
| Return visit (30+ min) | 38 | $3,115 | $66 |
| Removal of cerebrospinal fluid with lower back spinal tap for diagnostic test | 11 | $768 | $70 |
2014: 4 services
| Long return visit (40+ min) | 142 | $17,713 | $88 |
| New patient visit (60+ min) | 117 | $16,032 | $137 |
| Extended office or other outpatient service, first hour | 111 | $9,322 | $82 |
| Return visit (30+ min) | 39 | $2,965 | $64 |
2013: 3 services
| New patient visit (60+ min) | 75 | $10,465 | $140 |
| Long return visit (40+ min) | 47 | $5,636 | $92 |
| Extended office or other outpatient service, first hour | 31 | $2,684 | $79 |
Drugs they prescribed that Part D paid
$273,987
Pharmacies billed $273,987 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 686) in 2024. At or below the middle of the specialty; the typical neuropsychiatry clinician is at 0%.
630 generic and 56 brand-name prescriptions · $273,987 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Austedo | 19 | $230,236 | $12,118 |
| Rivastigmine | 77 | $13,366 | $174 |
| Memantine | 35 | $3,836 | $110 |
| Donepezil | 207 | $2,936 | $14 |
| Rivastigmine | 33 | $2,258 | $68 |
See all 10 drugs
| Austedo | 19 | $230,236 | $12,118 |
| Rivastigmine | 77 | $13,366 | $174 |
| Memantine | 35 | $3,836 | $110 |
| Donepezil | 207 | $2,936 | $14 |
| Rivastigmine | 33 | $2,258 | $68 |
| Sertraline | 150 | $724 | $5 |
| Mirtazapine | 44 | $544 | $12 |
| Escitalopram | 48 | $507 | $11 |
| Donepezil Hcl Odt | 20 | $326 | $16 |
| Risperidone | 11 | $56 | $5 |
Year by year
| 2024 | 686 | 132 | 0% (0) | 8% | $273,987 |
| 2023 | 635 | 121 | 0% (0) | 5% | $199,054 |
| 2022 | 526 | 120 | 0% (0) | 5% | $56,463 |
| 2021 | 469 | 103 | 0% (0) | 7% | $43,306 |
| 2020 | 595 | 109 | 0% (0) | 9% | $51,259 |
| 2019 | 667 | 119 | 0% (0) | 7% | $57,741 |
| 2018 | 691 | 123 | 0% (0) | 8% | $84,682 |
| 2017 | 707 | 120 | 0% (0) | 11% | $139,621 |
| 2016 | 744 | 110 | 0% (0) | 8% | $42,839 |
| 2015 | 683 | 117 | 0% (0) | 14% | $39,971 |
| 2014 | 387 | 68 | 0% (0) | 17% | $25,592 |
| 2013 | 99 | 29 | 0% (0) | 31% | $13,478 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 8 drugs
| Rivastigmine | 42 | $12,599 | $300 |
| Donepezil | 255 | $4,686 | $18 |
| Rivastigmine | 28 | $2,861 | $102 |
| Memantine Hcl Er | 12 | $2,764 | $230 |
| Memantine | 26 | $2,190 | $84 |
| Sertraline | 134 | $1,039 | $8 |
| Mirtazapine | 38 | $824 | $22 |
| Escitalopram | 31 | $592 | $19 |
2022: 9 drugs
| Rivastigmine | 27 | $3,504 | $130 |
| Donepezil | 219 | $3,450 | $16 |
| Rivastigmine | 26 | $1,778 | $68 |
| Sertraline | 110 | $1,023 | $9 |
| Memantine | 31 | $723 | $23 |
| Mirtazapine | 22 | $603 | $27 |
| Carbidopa-Levodopa | 13 | $386 | $30 |
| Escitalopram | 20 | $382 | $19 |
| Quetiapine | 13 | $278 | $21 |
2021: 8 drugs
| Rivastigmine | 46 | $9,909 | $215 |
| Donepezil | 158 | $3,078 | $19 |
| Sertraline | 100 | $1,266 | $13 |
| Carbidopa-Levodopa | 17 | $851 | $50 |
| Memantine | 22 | $802 | $36 |
| Rivastigmine | 13 | $789 | $61 |
| Escitalopram | 31 | $536 | $17 |
| Mirtazapine | 16 | $527 | $33 |
2020: 10 drugs
| Rivastigmine | 53 | $14,932 | $282 |
| Exelon | 13 | $14,908 | $1,147 |
| Tetrabenazine | 11 | $7,691 | $699 |
| Donepezil | 192 | $3,456 | $18 |
| Rivastigmine | 31 | $2,073 | $67 |
| Citalopram Hbr | 12 | $1,079 | $90 |
| Sertraline | 122 | $1,066 | $9 |
| Mirtazapine | 26 | $928 | $36 |
| Escitalopram | 62 | $708 | $11 |
| Memantine | 23 | $648 | $28 |
2019: 12 drugs
| Rivastigmine | 42 | $14,719 | $350 |
| Memantine Hcl Er | 21 | $5,927 | $282 |
| Donepezil | 236 | $3,597 | $15 |
| Citalopram Hbr | 27 | $2,233 | $83 |
| Rivastigmine | 20 | $1,929 | $96 |
| Mirtazapine | 46 | $1,770 | $38 |
| Sertraline | 104 | $990 | $10 |
| Escitalopram | 68 | $881 | $13 |
| Memantine | 19 | $527 | $28 |
| Quetiapine | 14 | $244 | $17 |
| Carbidopa-Levodopa | 13 | $242 | $19 |
| Trazodone | 12 | $115 | $10 |
2018: 13 drugs
| Tetrabenazine | 12 | $27,625 | $2,302 |
| Rivastigmine | 46 | $20,753 | $451 |
| Exelon | 17 | $16,268 | $957 |
| Donepezil | 250 | $3,469 | $14 |
| Memantine Hcl Er | 16 | $3,352 | $210 |
| Rivastigmine | 26 | $2,781 | $107 |
| Citalopram Hbr | 34 | $1,366 | $40 |
| Sertraline | 101 | $1,266 | $13 |
| Mirtazapine | 38 | $1,034 | $27 |
| Escitalopram | 50 | $693 | $14 |
| Quetiapine | 17 | $206 | $12 |
| Trazodone | 16 | $188 | $12 |
| Clonazepam | 12 | $68 | $6 |
2017: 14 drugs
| Exelon | 24 | $21,513 | $896 |
| Rivastigmine | 55 | $20,889 | $380 |
| Namenda Xr | 15 | $6,770 | $451 |
| Donepezil | 250 | $3,520 | $14 |
| Rivastigmine | 30 | $2,610 | $87 |
| Mirtazapine | 32 | $1,946 | $61 |
| Memantine | 25 | $1,318 | $53 |
| Sertraline | 63 | $719 | $11 |
| Escitalopram | 44 | $480 | $11 |
| Quetiapine | 39 | $369 | $9 |
| Carbidopa-Levodopa | 15 | $321 | $21 |
| Trazodone | 27 | $234 | $9 |
| Citalopram Hbr | 40 | $213 | $5 |
| Clonazepam | 11 | $68 | $6 |
2016: 11 drugs
| Exelon | 19 | $14,397 | $758 |
| Namenda Xr | 15 | $6,833 | $456 |
| Rivastigmine | 26 | $6,249 | $240 |
| Donepezil | 373 | $4,601 | $12 |
| Mirtazapine | 31 | $2,763 | $89 |
| Memantine | 26 | $2,033 | $78 |
| Quetiapine | 45 | $1,065 | $24 |
| Escitalopram | 49 | $453 | $9 |
| Sertraline | 23 | $364 | $16 |
| Citalopram Hbr | 70 | $360 | $5 |
| Trazodone | 34 | $220 | $6 |
2015: 10 drugs
| Exelon | 25 | $14,885 | $595 |
| Namenda | 24 | $8,420 | $351 |
| Namenda Xr | 13 | $6,606 | $508 |
| Donepezil | 357 | $3,510 | $10 |
| Citalopram Hbr | 100 | $685 | $7 |
| Carbidopa-Levodopa | 18 | $580 | $32 |
| Sertraline | 42 | $275 | $7 |
| Escitalopram | 27 | $238 | $9 |
| Trazodone | 28 | $161 | $6 |
| Quetiapine | 11 | $157 | $14 |
2014: 7 drugs
| Exelon | 43 | $15,974 | $371 |
| Namenda | 15 | $4,376 | $292 |
| Donepezil | 201 | $2,271 | $11 |
| Citalopram Hbr | 58 | $317 | $5 |
| Trazodone | 23 | $145 | $6 |
| Sertraline | 12 | $85 | $7 |
| Escitalopram | 11 | $76 | $7 |
2013: 2 drugs
| Namenda | 21 | $6,845 | $326 |
| Donepezil | 59 | $2,058 | $35 |
Money from drug and device companies
$29 in 2025
| 2025 | 1 | 1 | None | $29 |
| 2024 | 2 | 2 | $4,680 | $4,746 |
| 2022 | 2 | 13 | None | $2,000 |
| 2019 | 4 | 4 | $1,020 | $1,303 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Genentech | None | $29 | 1 payment
|
See the published payment
| Genentech | Meals · 2025-12-02 | None | $29 |
See earlier years (2024, 2022, 2019)
2024: $4,746
| Eisai | Leqembi | $4,680 | 1 payment
|
| Biogen | None | $66 | 1 payment
|
2022: $2,000
| Biogen | None | $1,898 | 12 payments
|
| Eisai | None | $103 | 1 payment
|
2019: $1,303
| Genentech USA | Activase | $1,020 | 1 payment
|
| Medtronic USA | Activa | $169 | 1 payment
|
| Biogen | None | $63 | 1 payment
|
| Eisai | None | $51 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Biogen, Inc. · A Study To Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer'S Disease Who Had Previously Participated in the Aducanumab Studies 221ad103, 221ad301, 221ad302 and 221ad205 · 2021 | Their institution | $386,718 |
| Novartis Pharmaceuticals Corporation · A 5 Year Prospective Study of An Anti Amyloid Therapy Cad106 Or Cnp520 in Slowing and Or Postponing Cognitive Decline in Asymptomatic Apoe 4 Homozygotes at Risk for Developing Alzheimers Disease Dementia · 2019 | Their institution | $349,537 |
| Biogen, Inc. · Phase 3b Open-Label, Multicenter, Safety Study of Biib037 (Aducanumab) in Subjects With Alzheimer'S Disease Who Had Previously Participated in the Aducanumab Studies221ad103, 221ad301, 221ad302 and 221ad205 · 2022 | Their institution | $344,819 |
| Biogen, Inc. · 221ad302 Phase 3 Study of Aducanumab (Biib037) in Early Alzheimer'S Disease · 2019 | Their institution | $341,775 |
| Eisai Inc. · Ahead 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With An Extension Phase To Evaluate Efficacy and Safety of Treatment With Ban2401 in Subjects With Preclinical Alzheimer'S Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer'S Disease and Intermediate Amyloid (A3 Trial) · 2023 | Their institution | $327,750 |
| Biogen, Inc. · Phase 2 Study of Biib092 in Participants With Early Alzheimer'S Disease · 2019 | Their institution | $311,367 |
| Eisai Inc. · A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study To Evaluate Efficacy and Safety of Treatment With Ban2401 in Subjects With Preclinical Alzheimer'S Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer'S Disease and Intermediate Amyloid (A3 Trial) · 2025 | Their institution | $306,515 |
| Novartis Pharmaceuticals Corporation · A Randomized Double Blind Placebo Controlled Parallel Group Study To Evaluate the Efficacy of Two Doses of Cnp520 in Participants at Risk for the Onset of Clinical Symptoms of Ad · 2019 | Their institution | $302,681 |
| Biogen, Inc. · Phase 3b Open-Label, Multicenter, Safety Study of Biib037 (Aducanumab) in Subjects With Alzheimers Disease Who Had Previously Participated in the Aducanumab Studies221ad103, 221ad301, 221ad302 and 221ad205 · 2024 | Their institution | $280,789 |
| Eli Lilly and Company · Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease · 2022 | Their institution | $265,907 |
| Biogen, Inc. · Phase 2 Study of Biib092 in Participants With Early Alzheimer'S Disease · 2020 | Their institution | $253,155 |
| Genentech, Inc. · Phase II Study of Anti Tau in Prodromal To Mild Ad · 2019 | Their institution | $231,550 |
| Janssen Research & Development, LLC · A Randomized Double Blind Placebo Controlled Parallel Group Multi Center Study To Assess the Efficacy and Safety of Jnj63733657 An Antitau Monoclonal Antibody in Participants With Early Alzheimer'S Disease · 2023 | Their institution | $218,333 |
| Eli Lilly and Company · A Study of Donanemab (Ly3002813) in Participants With Early Alzheimer'S Disease (Trailblazer-Alz 2) · 2023 | Their institution | $199,406 |
| Biogen, Inc. · Phase 2 Study of Biib092 in Participants With Early Alzheimer'S Disease · 2021 | Their institution | $180,247 |
| Novartis Pharmaceuticals Corporation · A 5 Year Prospective Study of An Anti Amyloid Therapy Cad106 Or Cnp520 in Slowing and Or Postponing Cognitive Decline in Asymptomatic Apoe 4 Homozygotes at Risk for Developing Alzheimers Disease Dementia · 2020 | Their institution | $179,661 |
| Eli Lilly and Company · Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease · 2021 | Their institution | $174,571 |
| Eisai Inc. · A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With An Open-Label Extension Phase To Confirm Safety and Efficacy of Ban2401 in Subjects With Early Alzheimer'S Disease · 2024 | Their institution | $150,050 |
| Genentech, Inc. · Phase II Study of Anti Tau in Prodromal To Mild Ad · 2020 | Their institution | $138,059 |
| Genentech, Inc. · Digital in Ad Poc Study · 2021 | Their institution | $136,612 |
| Janssen Research & Development, LLC · A Randomized Double Blind Placebo Controlled Parallel Group Multi Center Study To Assess the Efficacy and Safety of Jnj63733657 An Antitau Monoclonal Antibody in Participants With Early Alzheimer'S Disease · 2022 | Their institution | $122,569 |
| Janssen Research & Development, LLC · A Randomized Double Blind Placebo Controlled Parallel Group Multi Center Study To Assess the Efficacy and Safety of Jnj63733657 An Antitau Monoclonal Antibody in Participants With Early Alzheimer'S Disease · 2025 | Their institution | $119,620 |
| Eli Lilly and Company · Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease · 2024 | Their institution | $113,206 |
| Biogen, Inc. · Phase 3b Open-Label, Multicenter, Safety Study of Biib037 (Aducanumab) in Subjects With Alzheimers Disease Who Had Previously Participated in the Aducanumab Studies221ad103, 221ad301, 221ad302 and 221ad205 · 2023 | Their institution | $108,944 |
| Janssen Research & Development, LLC · A Randomized Double Blind Placebo Controlled Parallel Group Multi Center Study To Assess the Efficacy and Safety of Jnj63733657 An Antitau Monoclonal Antibody in Participants With Early Alzheimer'S Disease · 2024 | Their institution | $105,151 |
| UCB SA · A Patient- and Investigator-Blind, Placebo-Controlled Study To Evaluate the Efficacy, Safety, and Tolerability of Bepranemab (Ucb0107) in Study Participants With Prodromal To Mild Alzheimers Disease (Ad), Followed By An Open-Label Extensio · 2022 | Their institution | $75,707 |
| Eisai Inc. · A Study To Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer'S Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer'S Disease and Intermediate Amyloid · 2021 | Their institution | $72,560 |
| Merck Sharp & Dohme Corporation · A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial To Study the Efficacy and Safety of Mk-8931 Sch 900931 in Subjects With Amnestic Mild Cognitive Impairment Due To Alzheimer S Disease Prodromal Ad. · 2019 | Their institution | $64,093 |
| Eisai Inc. · A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With An Open-Label Extension Phase To Confirm Safety and Efficacy of Ban2401 in Subjects With Early Alzheimer'S Disease · 2021 | Their institution | $50,791 |
| Genentech, Inc. · Prodromal To Mild Ad · 2019 | Their institution | $50,771 |
| Biogen, Inc. · Multiple Dose Study of Aducanumab (Biib037) (Recombinant, Fully Human Anti-A Igg1 Mab) in Participants With Prodromal Or Mild Alzheimer'S Disease · 2019 | Their institution | $41,825 |
| Eisai Inc. · A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With An Open-Label Extension Phase To Confirm Safety and Efficacy of Ban2401 in Subjects With Early Alzheimer'S Disease · 2025 | Their institution | $39,365 |
| Genentech, Inc. · Phase II Study of Anti Tau in Prodromal To Mild Ad · 2021 | Their institution | $39,278 |
| Eisai Inc. · A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With An Open-Label Extension Phase To Confirm Safety and Efficacy of Ban2401 in Subjects With Early Alzheimer'S Disease · 2022 | Their institution | $38,030 |
| Biogen, Inc. · A Study To Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer'S Disease Who Had Previously Participated in the Aducanumab Studies 221ad103, 221ad301, 221ad302 and 221ad205 · 2020 | Their institution | $34,651 |
| Biogen, Inc. · 221ad302 Phase 3 Study of Aducanumab (Biib037) in Early Alzheimer'S Disease · 2020 | Their institution | $28,583 |
| Genentech, Inc. · Phase II Study for Moderate Ad · 2020 | Their institution | $28,404 |
| Genentech, Inc. · Digital in Ad Poc Study · 2022 | Their institution | $27,680 |
| ACADIA Pharmaceuticals Inc · Nuplazid · 2021 | Their institution | $18,656 |
| Genentech, Inc. · Phase II Study for Moderate Ad · 2019 | Their institution | $18,319 |
| Biogen, Inc. · An Observational Study Using Multimodal Sensors To Measure Cognitive Health in Adults and Distinguish Mild Cognitive Impairment From Normal Aging. · 2022 | This clinician | $15,019 |
| UCB SA · A Patient- and Investigator-Blind, Placebo-Controlled Study To Evaluate the Efficacy, Safety, and Tolerability of Bepranemab (Ucb0107) in Study Participants With Prodromal To Mild Alzheimer'S Disease (Ad), Followed By An Open-Label Extension Period · 2023 | Their institution | $13,148 |
| Eli Lilly and Company · Assessment of Safety and Efficacy of Subcutaneous Remternetug in Early Symptomatic Alzheimer'S Disease · 2025 | Their institution | $11,956 |
| Eisai Inc. · A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With An Open-Label Extension Phase To Confirm Safety and Efficacy of Ban2401 in Subjects With Early Alzheimer'S Disease · 2023 | Their institution | $11,612 |
| ACADIA Pharmaceuticals Inc · Nuplazid · 2022 | Their institution | $11,466 |
| Eisai Inc. · A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With An Open-Label Extension Phase To Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer'S Disease · 2020 | Their institution | $10,948 |
| Biogen, Inc. · Multiple Dose Study of Aducanumab (Biib037) (Recombinant, Fully Human Anti-A Igg1 Mab) in Participants With Prodromal Or Mild Alzheimer'S Disease · 2020 | Their institution | $9,529 |
| Biogen, Inc. · Multiple Dose Study of Aducanumab (Biib037) (Recombinant, Fully Human Anti-A Igg1 Mab) in Participants With Prodromal Or Mild Alzheimer'S Disease · 2021 | Their institution | $9,255 |
| Novartis Pharmaceuticals Corporation · A Randomized Double Blind Placebo Controlled Parallel Group Study To Evaluate the Efficacy of Two Doses of Cnp520 in Participants at Risk for the Onset of Clinical Symptoms of Ad · 2020 | Their institution | $8,799 |
| Eli Lilly and Company · Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease · 2025 | Their institution | $8,321 |
| Genentech, Inc. · Digital in Ad Poc Study · 2023 | Their institution | $8,136 |
| E.R. Squibb & Sons, L.L.C. · A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Evaluate the Efficacy and Safety of Karxt + Karx-Ec for the Treatment of Cognitive Impairment Associated With Mild-To-Moderate Alzheimers Disease (Mindset 2) · 2025 | Their institution | $5,343 |
| Eli Lilly and Company · Assessment of Safety and Efficacy of Intravenous Remternetug in Early Symptomatic Alzheimers Disease · 2025 | Their institution | $5,314 |
| Genentech, Inc. · Phase II Study for Moderate Ad · 2021 | Their institution | $1,867 |
| Genentech, Inc. · Prodromal To Mild Ad · 2021 | Their institution | $1,551 |
| Eli Lilly and Company · Assessment of Safety and Efficacy of Subcutaneous Remternetug in Early Symptomatic Alzheimer'S Disease · 2023 | This clinician | $1,358 |
| Eli Lilly and Company · Assessment of Safety and Efficacy of Subcutaneous Remternetug in Early Symptomatic Alzheimer'S Disease · 2023 | Their institution | $664 |
| Eli Lilly and Company · A Study of Donanemab (Ly3002813) in Participants With Early Alzheimer'S Disease (Trailblazer-Alz 2) · 2023 | This clinician | $380 |
| Eli Lilly and Company · Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease · 2022 | This clinician | $300 |
| Merck Sharp & Dohme Corporation · A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial To Study the Efficacy and Safety of Mk-8931 Sch 900931 in Subjects With Amnestic Mild Cognitive Impairment Due To Alzheimer S Disease Prodromal Ad. · 2021 | Their institution | $62 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1225299027
- Licence
- CA A104145California A104145: Current · expires 2028-03-31
- Trained
- Georgetown University School of Medicine, 2006
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 2084B0040X (2084B0040X); Neurology (2084N0400X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2008-06-24
- NPI last updated
- 2023-11-06
- NPI record certified
- 2023-11-06
This is when the NPI record was last certified, not a medical board exam.